In this short video, filmed at the ASTRO 2023 conference, Elena Nioutsikou, global programme director for MRI in RT, explains how Siemens Healthineers can make an impact on patient outcomes across the whole continuum of cancer care, by providing the flexibility to choose the imaging that best suits the user’s needs.

She goes on to outline how MR and CT can work together, with MR providing information about anatomy, but also unlocking functional information that could, for example, supply insights into the inhomogeneities in the tumour and potentially also help to adapt dose prescriptions.

Sabine Bernard, senior manager of product marketing radiation therapy solutions at Varian, a Siemens Healthineers company, then talks about new innovations, including HyperSight on TrueBeam and Edge radiotherapy systems (now 510(k) pending). She explains that a year ago, HyperSight was launched on Halcyon and Ethos, bringing image quality, precision and speed. Now this is available on TrueBeam and Edge as well, the company is looking forward to seeing how people will use those images to go beyond IGRT.

Ethos 2.0, also launched in 2023, will use the HyperSight images in a unique way to directly calculate the dose on HyperSight images acquired during the treatment – to increase both precision and speed. Bernard says that the company believes that HyperSight on TrueBeam, on Halcyon, on Edge, as well as on Ethos, will help users increase their confidence to deliver the best treatment to their patients. In addition, Siemens Healthineers also launched the MAGNETOM Free.Max RT edition, the industry’s first 80 cm-bore system. The MRI system has a low total cost of ownership, and as it doesn’t have a quench pipe, can be installed easily in radiotherapy bunkers.

Innovation is not only applicable to products, concludes Bernard, it also applies to how innovations are implemented in the clinic, which is why the company is sponsoring clinical trials and creating working groups to discuss the next steps in the radiotherapy journey.